re: bbaattmmaann sunday reading Hey Gibbler , from what I...

re: bbaattmmaann sunday reading Hey Gibbler , from what I understand , it is the trial doctor who is in charge of the trial , not Solbec . Millward is supposed to be one of the best . The trial is dose escalating and one of the endpoints is dose limiting toxicity . They explained that in the last report and also stated they had consulted specialists to confirm there was no lasting damage . The main purpose of a phase one is to establish the therapeutic and toxic levels . Its done . It is time consuming , as the patients are put on one at a time , at increasing doses , while everything has to be checked for adverse effects with enough time elapsed before proceeding to the next level .
They had put on another NSCLC patient , but withdrew due to needle phobia . Forget about the 1 in a thousand , if you read the Rational Therapeutics test results you will see RT found it at least twice as effective as a single agent against NSCLC than the best chemo combinations . Probably still a little early to claim 100% though .
The three responses reported were partial responses . That means greater than 50% tumour reduction by the RECIST criteria . That means a reduction of the largest tumour . The patients allowed onto this safety trial are in a terrible state and little response is expected . People just dont understand how good that result was . Most of the answers you want are out there .
The final trial report has yet to be released . I think the big question there , is time to progression (TTP) and survival time . I hope neither of those points have been reached . The >50% responses were exceptional at this point , some durable responses would be even better . All IMHO.
If you are a shareholder with Solbec , why dont you contact them with any concerns you have .
Cheers